Research programme: invariant natural killer T-cells therapeutics - SalvaRx

Drug Profile

Research programme: invariant natural killer T-cells therapeutics - SalvaRx

Alternative Names: iNKT therapeutics - SalvaRx

Latest Information Update: 05 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ludwig Institute for Cancer Research; University of Oxford
  • Developer SalvaRx
  • Class Immunotherapies; Lipids
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Mar 2016 Preclinical trials in Cancer in United Kingdom (Parenteral)
  • 22 Mar 2016 SalvaRx plans a phase I/II trial for Cancer in United Kingdom
  • 11 Mar 2016 Ludwig Institute grants license to iOx Therapeutics for development of anti-cancer treatments based on invariant natural killer T-cells
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top